A management metric for the pharmaceutical business that combines strong growth in pharmaceutical sales driven by new product launches and expanded indications with the management of an upper limit on R&D expenses as a percentage of sales. Including an increase in the candidate pipeline, the aim is to achieve both business-scale expansion and profitability and development-investment efficiency.